Voyager Therapeutics, Inc. (VYGR) financial statements and ratios from SEC XBRL: revenue $40.37M (TTM), net margin -296.5%, revenue growth -49.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $40.37M |
| Net Margin | -296.5% |
| Revenue Growth (YoY) | -49.5% |
| EPS Growth (YoY) | 80.5% |
| FCF Growth (YoY) | 617.2% |
| Price / Book | 1.17 |
| Price / Sales | 7.37 |
| FCF Yield | -122.3% |
| Altman Z-Score | -1.06 (distress) |
| Sector P/E (Healthcare) | 21.7 |
VYGR overview · VYGR earnings · VYGR KPIs · VYGR investor relations · VYGR ownership · VYGR peers · VYGR filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.